Psoriasis de novo or exacerbation by PD-1 checkpoint inhibitors

• Главные авторы: Zi Wan (Автор), Jiangyuan Huang (Автор), Xiaojie Ou (Автор), Shuang Lou (Автор), Jianji Wan (Автор), Zhu Shen (Автор)
• Формат: ‌
• Опубликовано: Sociedade Brasileira de Dermatologia, 2024-05-01T00:00:00Z.
• Предметы: article
• Online-ссылка: Connect to this object online.

Abstract PD-1 (programmed Death-1) immune checkpoint inhibitors have provided significant benefits to tumor patients. However, a considerable proportion of the patients develop immune-related adverse events (irAEs), of which cutaneous irAEs (cirAEs, e.g., psoriasis) occur relatively early. This revi...